Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin Therapy in Patients With Chronic Hepatitis C
| Autor: | Teresa M. Curto, Elizabeth C. Wright, Neal D. Freedman, Karen L. Lindsay, James E. Everhart, Rashmi Sinha |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Liver Cirrhosis
Male medicine.medical_specialty Time Factors Cirrhosis Hepatitis C virus Hepacivirus Interferon alpha-2 medicine.disease_cause Lower risk Antiviral Agents Coffee Gastroenterology Article Polyethylene Glycols chemistry.chemical_compound Interquartile range Internal medicine Ribavirin Odds Ratio medicine Humans Propensity Score Chi-Square Distribution Hepatology business.industry Interferon-alpha Odds ratio Hepatitis C Hepatitis C Chronic Middle Aged Viral Load medicine.disease Recombinant Proteins United States Logistic Models Treatment Outcome chemistry Hepatocellular carcinoma Immunology RNA Viral Drug Therapy Combination Female business Biomarkers |
| Zdroj: | Gastroenterology. 140:1961-1969 |
| ISSN: | 0016-5085 |
| DOI: | 10.1053/j.gastro.2011.02.061 |
| Popis: | High-level coffee consumption has been associated with reduced progression of pre-existing liver diseases and lower risk of hepatocellular carcinoma. However, its relationship with therapy for hepatitis C virus infection has not been evaluated.Patients (n=885) from the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial recorded coffee intake before retreatment with peginterferon α-2a (180 μg/wk) and ribavirin (1000-1200 mg/day). We assessed patients for early virologic response (2 log10 reduction in level of hepatitis C virus RNA at week 12; n=466), and undetectable hepatitis C virus RNA at weeks 20 (n=320), 48 (end of treatment, n=284), and 72 (sustained virologic response; n=157).Median log10 drop from baseline to week 20 was 2.0 (interquartile range [IQR], 0.6-3.9) among nondrinkers and 4.0 (IQR, 2.1-4.7) among patients that drank 3 or more cups/day of coffee (P trend.0001). After adjustment for age, race/ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to alanine aminotransferase, the IL28B polymorphism rs12979860, dose reduction of peginterferon, and other covariates, odds ratios for drinking 3 or more cups/day vs nondrinking were 2.0 (95% confidence interval [CI]: 1.1-3.6; P trend=.004) for early virologic response, 2.1 (95% CI: 1.1-3.9; P trend=.005) for week 20 virologic response, 2.4 (95% CI: 1.3-4.6; P trend=.001) for end of treatment, and 1.8 (95% CI: 0.8-3.9; P trend=.034) for sustained virologic response.High-level consumption of coffee (more than 3 cups per day) is an independent predictor of improved virologic response to peginterferon plus ribavirin in patients with hepatitis C. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|